Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT00034918 Completed - Breast Neoplasms Clinical Trials

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

Start date: May 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.

NCT ID: NCT00034827 Completed - Breast Neoplasms Clinical Trials

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Start date: January 2002
Phase: Phase 2
Study type: Interventional

CI-1040 is an experimental drug that is being tested in patients who have advanced colorectal and lung cancer who failed no more than one prior chemotherapy regimen, breast cancer who have failed no more than 2 prior regimens and in patients with pancreatic cancer who have received no prior chemotherapy. CI-1040 is taken orally twice daily with meals. Patients are required to have blood tests periodically while receiving treatment and will be monitored closely throughout the trial for possible side effects and for response.

NCT ID: NCT00034489 Completed - Breast Neoplasms Clinical Trials

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Start date: n/a
Phase: Phase 2
Study type: Interventional

This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.

NCT ID: NCT00034281 Completed - Breast Neoplasm Clinical Trials

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Start date: June 2002
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.

NCT ID: NCT00034125 Completed - Breast Neoplasms Clinical Trials

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Start date: n/a
Phase: Phase 3
Study type: Interventional

To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.

NCT ID: NCT00033514 Completed - Breast Cancer Clinical Trials

Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression

Start date: August 2001
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Combining trastuzumab with erlotinib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining trastuzumab with erlotinib as first-line therapy in treating women who have metastatic breast cancer associated with HER2/neu overexpression.

NCT ID: NCT00033397 Completed - Breast Cancer Clinical Trials

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

Start date: February 2002
Phase: N/A
Study type: Observational

RATIONALE: Comparing results of diagnostic procedures performed before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: Diagnostic trial to study magnetic resonance imaging (MRI) and biomarkers in women who are receiving chemotherapy before surgery for locally advanced breast cancer.

NCT ID: NCT00033384 Completed - Breast Cancer Clinical Trials

CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer

Start date: February 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of CI-1040 in treating patients who have metastatic or unresectable breast, colon, pancreatic, or non-small cell lung cancer.

NCT ID: NCT00033345 Completed - Breast Cancer Clinical Trials

Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer

Start date: January 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Indole-3-carbinol may be effective in preventing breast cancer. PURPOSE: Phase I trial to study the effectiveness of indole-3-carbinol in preventing breast cancer in nonsmoking women who are at high risk for breast cancer.

NCT ID: NCT00032136 Completed - Breast Cancer Clinical Trials

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Start date: December 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by reducing the production of estrogen. It is not yet known if exemestane is more effective than tamoxifen in preventing the recurrence of breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of exemestane with that of tamoxifen in treating postmenopausal women who have undergone surgery to remove early-stage breast cancer.